Emmaus Life Sciences announces submission of marketing authorisation application to Swissmedic; Ideogen to manage early access program

Emmaus Life Sciences

15 June 2021 - Emmaus Life Sciences anounced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus' application for marketing authorisation for Endari in Switzerland. 

In November 2020, Swissmedic granted Endari orphan drug status.

Read Emmaus Life Sciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Dossier , Switzerland